Evidence map›Paper›PMID 39224646›Full record

ReviewRSC advances2024

FDA-approved drugs containing dimethylamine pharmacophore: a review of the last 50 years.

Sandeep Bindra, Kuntal Bose, Amrutha Chandran Thekkantavida, Della Grace Thomas Parambi, Tariq G Alsahli, Manu Pant, Leena K Pappachen, Hoon Kim, Bijo Mathew

Abstract readReview
In one paragraph

Review in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sandeep BindraDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham Amrita Health Science Campus Kochi 682041 India bijomathew@aims.amrita.edu bijovilaventgu@gmail.com.
Kuntal BoseDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham Amrita Health Science Campus Kochi 682041 India bijomathew@aims.amrita.edu bijovilaventgu@gmail.com.
Amrutha Chandran ThekkantavidaDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham Amrita Health Science Campus Kochi 682041 India bijomathew@aims.amrita.edu bijovilaventgu@gmail.com.
Della Grace Thomas ParambiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Jouf University Sakaka Aljouf 72341 Saudi Arabia.
Tariq G AlsahliDepartment of Pharmacology, College of Pharmacy, Jouf University Sakaka Aljouf 72341 Saudi Arabia.
Manu PantSchool of Pharmacy, Graphic Era Hill University Dehradun 248002 India.
Leena K PappachenDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham Amrita Health Science Campus Kochi 682041 India bijomathew@aims.amrita.edu bijovilaventgu@gmail.com.
Hoon KimDepartment of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University Suncheon 57922 Republic of Korea hoon@sunchon.ac.kr.ORCID https://orcid.org/0000-0002-7203-3712
Bijo MathewDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham Amrita Health Science Campus Kochi 682041 India bijomathew@aims.amrita.edu bijovilaventgu@gmail.com.ORCID https://orcid.org/0000-0002-6658-4497

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dimethylamine (DMA) derivatives represent a promising class of compounds with significant potential in the field of medicinal chemistry. DMA derivatives exhibit a diverse range of pharmacological activities, including antimicrobial, antihistaminic, anticancer, and analgesic properties. Their unique chemical structure allows for the modulation of various biological targets, making them valuable candidates for the treatment of numerous diseases. Synthetic strategies for the preparation of DMA derivatives vary depending on the desired biological activity and target molecule. Common synthetic routes involve the modification of the DMA scaffold through functional group manipulation, scaffold hopping, or combinatorial chemistry approaches. Therapeutically, DMA derivatives have shown promise in the treatment of infectious diseases, especially bacterial infections. Additionally, by focusing on particular biochemical pathways involved in tumor growth and metastasis, DMA-based drugs have shown anticancer activity. In addition to their direct pharmacological effects, DMA derivatives can serve as valuable tools in drug delivery systems, prodrug design, and molecular imaging techniques, enhancing their utility in medicinal chemistry research. Overall, DMA derivatives represent a versatile class of compounds with immense potential in medicinal chemistry. Further research and development efforts are warranted to explore their full therapeutic capabilities and optimize their clinical utility in the treatment of various diseases. This article outlines the pharmacological properties, synthetic strategies, and therapeutic applications of DMA derivatives of FDA approved drugs, highlighting their importance in drug discovery and development.

Identifiers

PMID39224646
PMCPMC11367245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.